Goldenwell Biotech Files 8-K on Accountant Change
Ticker: GWLL · Form: 8-K · Filed: Nov 15, 2024 · CIK: 1800373
| Field | Detail |
|---|---|
| Company | Goldenwell Biotech, INC. (GWLL) |
| Form Type | 8-K |
| Filed Date | Nov 15, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: accountant-change, financial-statements, 8-k
Related Tickers: GDWL
TL;DR
GDWL changed accountants, filed financials. Watch for red flags.
AI Summary
Goldenwell Biotech, Inc. filed an 8-K on November 15, 2024, reporting changes in its certifying accountant and filing financial statements and exhibits. The report covers events as of November 13, 2024. The company is incorporated in Nevada and its principal executive offices are located in Hudson, Ohio.
Why It Matters
Changes in a company's certifying accountant can signal potential issues with financial reporting or internal controls, warranting investor attention.
Risk Assessment
Risk Level: medium — A change in certifying accountant, especially without further explanation, can sometimes indicate underlying financial or accounting concerns.
Key Players & Entities
- GOLDENWELL BIOTECH, INC. (company) — Registrant
- November 13, 2024 (date) — Earliest event reported
- November 15, 2024 (date) — Filing date
- Nevada (jurisdiction) — State of incorporation
- Hudson, Ohio (location) — Principal executive offices
FAQ
What is the specific reason for the change in Goldenwell Biotech's certifying accountant?
The filing indicates a change in the registrant's certifying accountant but does not provide specific details or reasons for this change in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on November 13, 2024.
What is Goldenwell Biotech, Inc.'s state of incorporation?
Goldenwell Biotech, Inc. is incorporated in Nevada.
Where are Goldenwell Biotech, Inc.'s principal executive offices located?
Goldenwell Biotech, Inc.'s principal executive offices are located at 581 Boston Mills Road, Suite 300, Hudson, Ohio 44087.
What type of SEC filing is this and what items are being reported?
This is a Form 8-K (Current Report) reporting on 'Changes in Registrant's Certifying Accountant' and 'Financial Statements and Exhibits'.
Filing Stats: 860 words · 3 min read · ~3 pages · Grade level 15.1 · Accepted 2024-11-15 15:01:52
Filing Documents
- gdwl_8k.htm (8-K) — 25KB
- gdwl_ex161.htm (EX-16.1) — 5KB
- gdwl_ex161img2.jpg (GRAPHIC) — 2KB
- 0001477932-24-007310.txt ( ) — 149KB
- gdwl-20241113.xsd (EX-101.SCH) — 6KB
- gdwl-20241113_lab.xml (EX-101.LAB) — 13KB
- gdwl-20241113_cal.xml (EX-101.CAL) — 1KB
- gdwl-20241113_pre.xml (EX-101.PRE) — 8KB
- gdwl-20241113_def.xml (EX-101.DEF) — 2KB
- gdwl_8k_htm.xml (XML) — 4KB
01 Changes in Registrant's Certifying Accountant
Item 4.01 Changes in Registrant's Certifying Accountant (a) On November 13, 2024, Goldenwell Biotech, Inc. (the "Company") notified Yusufali & Associates, LLC ("Yusufali & Associates") that the Company had dismissed Yusufali & Associates as the independent registered public accounting firm of the Company. The Board of Directors of the Company recommended and approved the dismissal. The Securities and Exchange Commission has notified the Company that Public Company Accounting Oversight Board has revoked the registration Yusufali & Associates. The reports of Yusufali & Associates regarding the Company's financial statements as of December 31, 2023 and 2022, and the related consolidated statements of operations and comprehensive loss, consolidated statements of changes in stockholders' equity, and consolidated statements of cash flows for the years then ended, contained no adverse opinion or disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope, or accounting principle. The reports of Yusufali & Associates, however, stated that there is substantial doubt about the Company's ability to continue as a going concern. For the years ended December 31, 2023 and 2022, and during the subsequent interim period through the date of dismissal, the Company had no disagreement with Yusufali & Associates on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreement, if not resolved to the satisfaction of Yusufali & Associates, would have caused them to make reference thereto in their report on the Company's financial statements for such years ended December 31, 2023 and 2022, and during the subsequent interim period through the date of dismissal. There were no reportable events, as listed in Item 304(a)(1)(v) of Regulation S-K. The Company provided Yusufali & Associates a copy of the above disclosures and requested Yusufali & Associates to furnish a letter addressed to
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits: Exhibit Description 16.1 Letter from Yusufali & Associates, LLC, dated November 14, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GOLDENWELL BIOTECH, INC. Date: November 14, 2024 By: /s/ Shuang Liu Name: Shuang Liu Title: Chief Executive Officer 3